Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jul;103(7):e311-e314.
doi: 10.3324/haematol.2017.184754. Epub 2018 Mar 15.

The impact of the introduction of bortezomib on dialysis independence in multiple myeloma patients with renal impairment: a nationwide Dutch population-based study

Berdien E Oortgiesen  1 , Roshna Azad  2 , Marc H Hemmelder  3 , Robby E Kibbelaar  4 , Nic J G M Veeger  5   6 , Joost C de Vries  7 , Eric N van Roon  8 , Mels Hoogendoorn  7
Affiliations

The impact of the introduction of bortezomib on dialysis independence in multiple myeloma patients with renal impairment: a nationwide Dutch population-based study

Berdien E Oortgiesen et al. Haematologica. 2018 Jul.
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Percentage of patients achieving Dialysis Independence within 4 years after starting dialysis. Hazard ratios were derived from a time-dependent model in which the effect of treatment (pre- vs. post-guideline) was divided in an early-on effect and the effect after one year of dialysis dependence. A hazard ratio >1 indicates an increased ‘risk’ of achieving Dialysis Independence resulting from the post-guideline versus the pre-guideline treatment.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Dimopoulos MA, Terpos E, Chanan-Khan A, et al. Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group J Clin Oncol. 2010;28(33):4976–4984. - PubMed
    1. San-Miguel JF, Richardson PG, Sonneveld P, et al. Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study Leukemia. 2008;22(4):842–849. - PubMed
    1. Dimopoulos MA, Roussou M, Gkotzamanidou M, et al. The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma Leukemia. 2013;27(2):423–429. - PubMed
    1. Sonneveld P, Zweegman S, Vellenga E, Wittebol S, Sinnige H, Meijer E. Guidelines for treatment of plasma cell dyscrasias in 2010 Ned Tijdschr Hematol. 2010;7:84–94.
    1. Tsakiris DJ, Stel VS, Finne P, et al. Incidence and outcome of patients starting renal replacement therapy for end-stage renal disease due to multiple myeloma or light-chain deposit disease: an ERA-EDTA Registry study Nephrol Dial Transplant. 2010;25(4):1200–1206. - PubMed

MeSH terms

  NODES
INTERN 3
twitter 2